Tropin-α-formylphenylacetat | 854641-97-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: Tropin-α-formylphenylacetat
• 英文别名: α-Formylphenylessigsaeuretropinester；3-oxo-2-phenyl-propionic acid tropan-3-yl ester；(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-oxo-2-phenylpropanoate
• CAS: 854641-97-7
• 化学式: C₁₇H₂₁NO₃
• 分子量: 287.359
• InChiKey: RMBZQGMKGCCRKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Novel Bicyclic Pyridinones
  申请人：Pettersson Martin Youngjin

  公开号：US20120252758A1

  公开（公告）日：2012-10-04

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受的盐被披露，其中所述化合物具有如本文所定义的Formula I的结构。相应的药物组合物、治疗方法、合成方法和中间体也被披露。
• [EN] 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS<br/>[FR] LIGANDS 6,7,8,9-TÉTRAHYDRO-5H-PYRIDO[2,3-D]AZÉPINE DU RÉCEPTEUR D3 DE LA DOPAMINE
  申请人：PFIZER

  公开号：WO2017122116A1

  公开（公告）日：2017-07-20

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.

  本发明提供了Formula (I)的化合物及其药学上可接受的盐，其中变量R1、R2、R3、R4、R5、a和A如本文所定义；制备方法；制备中使用的中间体；以及含有这种化合物或盐的组合物，以及它们用于治疗D3介导的（或与D3相关的）疾病，包括物质成瘾、物质滥用、精神分裂症（例如其认知症状）、认知障碍（例如与精神分裂症、阿尔茨海默病或帕金森病相关的认知障碍）、帕金森病、狂躁症、焦虑、冲动控制障碍、性功能障碍和抑郁症等疾病的用途。
• 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
  申请人：PFIZER INC.

  公开号：US20180208607A1

  公开（公告）日：2018-07-26

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

  本发明在一定程度上提供了Formula I的化合物： 及其药用盐；制备方法；制备中使用的中间体；以及含有这些化合物或盐的组合物，以及它们用于治疗MAGL介导的疾病和紊乱，包括但不限于疼痛、炎症性紊乱、抑郁症、焦虑症、阿尔茨海默病、代谢紊乱、中风或癌症。
• METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS
  申请人：TUFTS MEDICAL CENTER

  公开号：US20160052982A1

  公开（公告）日：2016-02-25

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备可溶性脂质化配体药剂的方法，包括配体实体和脂质实体，并在某些实施例中提供了这些组分的相关参数，从而使得能够适当选择组分来组装出针对任何感兴趣的靶点的活性药剂。
• AMINO-HETEROCYCLIC COMPOUNDS
  申请人：Claffey Michelle M.

  公开号：US20100190771A1

  公开（公告）日：2010-07-29

  The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

  这项发明提供了式（I）中的PDE9抑制化合物，以及其药学上可接受的盐，其中R1、R2、R3、A和n的定义如本文所述。还提供了含有式I中化合物的药物组合物，并且提供了在治疗神经退行性和认知障碍疾病，如阿尔茨海默病和精神分裂症中的用途。